Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

@article{Kuske2018ImmunomodulatoryEO,
  title={Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy},
  author={Marvin Kuske and D. Westphal and R. Wehner and M. Schmitz and S. Beissert and C. Praetorius and F. Meier},
  journal={Pharmacological Research},
  year={2018},
  volume={136},
  pages={151–159}
}
ABSTRACT Targeted therapy with BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provides rapid disease control with high response rates in patients with BRAF‐mutant metastatic melanoma. However, the majority of patients develop resistance to therapy during the course of therapy. Immune checkpoint inhibitors show a slower onset of action with lower response rates, with responders showing sustained response. The combination of BRAFi/MEKi and immune checkpoint inhibitors combines the hope for a… Expand
BRAF Gene and Melanoma: Back to the Future
Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
...
1
2
3
4
...

References

SHOWING 1-10 OF 73 REFERENCES
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
...
1
2
3
4
5
...